Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Non-Current Assets (2019 - 2025)

Keros Therapeutics' Other Non-Current Assets history spans 7 years, with the latest figure at $1.4 million for Q3 2025.

  • For Q3 2025, Other Non-Current Assets changed 0.0% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, changed 0.0%, while the annual FY2024 figure was $1.4 million, 20.75% up from the prior year.
  • Other Non-Current Assets reached $1.4 million in Q3 2025 per KROS's latest filing, up from $463000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.4 million in Q3 2024 to a low of $115000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $1.1 million, with a median of $1.3 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 1054.78% in 2021, then crashed 61.8% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then fell by 9.57% to $1.2 million in 2023, then grew by 20.75% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Other Non-Current Assets are $1.4 million (Q3 2025), $463000.0 (Q1 2025), and $1.4 million (Q4 2024).